An expanded access record providing ficlatuzumab in Mullerian Mixed Tumor of Ovary, sponsored by AVEO Pharmaceuticals, Inc.. No longer available at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-29.
Sponsored by AVEO Pharmaceuticals, Inc. · Expanded access
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to patient 0001-000412, who was previously enrolled under protocol P05538 and whom the investigator believes is deriving clinical benefit from ficlatuzumab treatment.
2,695 studies on the registry are indexed under Ovarian Neoplasms; 726 are open to participants now.
Browse Ovarian Neoplasms studies →AVEO Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
Also known as: AV-299, SCH 900105
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AVEO Pharmaceuticals, Inc.